Alopexx, Inc. announced that Daniel Vlock, MD, Co-Founder, Chief Executive Officer and Chairman of the Board of Alopexx, is scheduled to present at IDWeek's 2023's  New Antimicrobials in the Pipeline symposium being held October 11-15, 2023 in Boston, MA. Dr. Vlock will present pre-clinical and clinical data on Alopexx's monoclonal antibody (MAb) F598, a novel immunotherapeutic that targets PNAG.  MAbs as immunotherapies for infectious agents have a strong appeal but only a few are licensed for preventative use against limited diseases.

Limitations include the high specificity of MAbs for strains of microbes, a need for a diagnostic test to indicate which MAb would be appropriate and finding a sufficient window between diagnosis of the infection and clinical efficacy of these specific MAbs. An innovative and groundbreaking approach would be the development of a broad-spectrum immunotherapeutic MAb that could be used in a clinical setting for prevention of a broad range of infections or clinical disease indicators. Alopexx MAb F598 is a fully human IgG1 MAb to the conserved surface polysaccharide, PNAG, expressed by a wide range of microbial pathogens, including all of the ESKAPE organisms except P. aeruginosa.

Extensively published pre-clinical results show MAb F598 can protect against a range of non-viral microbial infections and there is no detectable binding to human tissues. It is being developed for therapeutic and prophylactic use in newly admitted intensive care unit (ICU) patients to ascertain the effect on infections in this setting.